Positron emission tomography-computed tomography and 4-hydroxynonenal-histidine immunohistochemistry reveal differential onset of lipid peroxidation in primary lung cancer and in pulmonary metastasis of remote malignancies

Redox Biology

Volumn 11, Issue , 2017, Pages 600-605

  Živković, Nevenka Piskač ^a   Petrovečki, Mladen ^a   Lončarić, Čedna Tomasović ^a   Nikolić, Igor ^a   Waeg, Georg ^b   Jaganjac, Morana ^c   Žarković, Kamelija ^d   Žarković, Neven ^e  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF GRAZ   (Austria)

^c Anti Doping Lab ^*  (Qatar)

^d KBC Zagreb   (Croatia)

^e RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

4 hydroxynonenal (HNE); Cell growth regulation; Immunohistochemistry; Inflammation; Lipid peroxidation (LPO); Positron emission tomography and computed tomography (PET CT)

Indexed keywords

4 HYDROXYNONENAL; HISTIDINE; 4-HYDROXY-2-NONENAL; ALDEHYDE;

ADULT; ARTICLE; CANCER CELL; CANCER GRADING; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; FIBROBLAST; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIPID PEROXIDATION; LUNG CANCER; LUNG METASTASIS; LUNG TUMOR; LYMPHOCYTE COUNT; MACROPHAGE; MALE; NEUTROPHIL COUNT; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; TUMOR VOLUME; AGED; CHEMISTRY; DIAGNOSTIC IMAGING; LUNG; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; SECONDARY;

ADULT; AGED; ALDEHYDES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY;

EID: 85009892607     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.01.005     Document Type: Article

References (44)

1. [1] Warburg, O., On the origin of cancer cells. Science 123 (1956), 309–314.
2. [2] Ping, M., Shile, S., Xiaoguang, S., Jianjun, L., Gang, H., Lactate dehydrogenase a in cancer: a promising target for diagnosis and therapy. IUBMB Life 65 (2013), 904–910.
3. [3] Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat. Rev. Cancer 11 (2011), 85–95.
4. [4] Lowe, V.J., Naunheim, K.S., Positron emission tomography in lung cancer. Ann. Thorac. Surg., 65, 1998, 1821.
5. [5] Dewan, N.A., Gupta, N.C., Redepenning, L.S., Phalen, J.J., Frick, M.P., Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules, Potential role in evaluation and management. Chest 104 (1993), 997–1002.
6. [6] Lowe, V.J., Hoffman, J.M., DeLong, D.M., Patz, E.F., Coleman, R.E., Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J. Nucl. Med., 35, 1994, 1771.
7. [7] Bar-Shalom, R., Kagna, O., Israel, O., Guralnik, L., Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-flouro-2-deoxy-D-glucoseavidity on positron emission tomography/computed tomography. Cancer, 113, 2008, 3213.
8. [8] Michael, K., Gould, M.S., Courtney, C., Maclean, B.A., Ware, G., Chara, E., et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285 (2001), 914–924.
9. [9] Naidich, D.P., Bankier, A.A., MacMahon, H., Schaefer-Prokop, C.M., Pistolesi, M., Goo, J.M., et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner society. Radiology, 266, 2013, 304.
10. [10] Vansteenkiste, J.F., Stroobants, S.S., PET scan in lung cancer: current recommendations and innovation. J. Thorac. Oncol., 1, 2006, 71.
11. [11] Ollenberger, G.P., Knight, S., Tauro, A.J., False positive FDG positron emission tomography in pulmonary amyloidosis. Clin. Nucl. Med. 29 (2004), 657–658.
12. [12] Alavi, A., Gupta, N., Alberini, J.L., Hickeson, M., Adam, L.E., Bhargava, P., et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin. Nucl. Med. 32 (2002), 293–321.
13. [13] Sies, H., Oxidative stress: oxidants and antioxidants. Exp. Physiol. 82 (1997), 291–295.
14. [14] Dröge, W., Free radicals in the physiological control of cell function. Physiol. Rev. 82 (2002), 47–95.
15. [15] Esterbauer, H., Schaur, R.J., Zollner, H., Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Rad. Biol. Med. 11 (1991), 81–128.
16. [16] Žarković, N., Žarković, K., Schaur, R.J., Stolc, S., Schlag, G., Redl, H., et al. 4-Hydroxynonenal as a second messenger of free radicals and growth modifying factor. Life Sci. 65 (1999), 1901–1904.
17. [17] Dianzani, M.U., 4-Hydroxynonenal and cell signalling. Free Rad. Res. 28 (1997), 553–559.
18. [18] Zarkovic, K., Juric, G., Waeg, G., Kolenc, D., Zarkovic, N., Immunohistochemical appearance of HNE-protein conjugates in human astrocytomas. BioFactors 24 (2005), 33–40.
19. [19] Barrera, S., Pizzimenti, S., Dianzani, M.U., Lipid peroxidation: control of cell proliferation, cell differentiation and cell death. Mol. Asp. Med. 29 (2008), 1–8.
20. [20] Zarkovic, N., 4-Hydroxynonenal as a bioactive marker of pathophysiological processes. Mol. Asp. Med. 24 (2003), 281–291.
21. [21] Cipak, A., Mrakovcic, L., Ciz, M., Lojek, A., Mihaylova, B., Goshev, I., et al. Growth suppression of human breast carcinoma stem cells by lipid peroxidation product 4-hydroxy-2-nonenal and hydroxyl radical-modified collagen. ABP 57 (2010), 165–171.
22. [22] Fortunati, N., Manti, R., Birocco, N., Pugliese, M., Brignardello, E., Ciuffreda, L., et al. Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncol. Rep. 18 (2007), 1517–1521.
23. [23] Esme, H., Cemek, M., Sezer, M., Saglam, H., Demir, A., Melek, H., et al. High levels of oxidative stress in patients with advanced lung cancer. Respirology 13 (2008), 112–116.
24. [24] Borovic, S., Cipak, A., Meinitzer, A., Kejla, Z., Perovic, D., Waeg, G., et al. Differential effect of 4-hydroxynonenal on normal and malignant mesenchimal cells. Redox Rep. 207 (2007), 50–54.
25. [25] Singhal, S.S., Yadav, S., Drake, K., Singhal, J., Awasthi, S., Hsf-1 and POB1 induce drug sensitivity and apoptosis by inhibiting Ralbp1. J. Biol. Chem. 283 (2008), 19714–19729.
26. [26] Kansanen, E., Kuosmanen, S.M., Leinonen, H., Levonen, A.L., The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 1 (2013), 45–49.
27. [27] Jaramillo, M.C., Zhang, D.D., The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27 (2013), 2179–2191.
28. [28] Lee, S., Lim, M.J., Kim, M.H., Yu, C.H., Yun, Y.S., Ahn, J., et al. An effective strategy for increasing the radiosensitivity of human lung cancer cells by blocking Nrf2-dependent antioxidant responses. Free RadicBiol. Med. 53 (2012), 807–816.
29. [29] Mahaffey, C.M., Zhang, H., Rinna, A., Holland, W., Mack, P.C., Forman, H.J., Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma. Free RadicBiol. Med. 46 (2009), 1650–1657.
30. [30] Bauer, G., Zarkovic, N., Revealing mechanisms of selective, concentration-dependent potentials of 4-hydroxy-2-nonenal to induce apoptosis in cancer cells through inactivation of membrane-associated catalase. Free RadicBiol. Med. 81 (2015), 128–144.
31. [31] Reuter, S., Gupta, S.C., Chaturvedi, M.M., Aggarwal, B.B., Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med. 49 (2010), 1603–1616.
32. [32] Westermarck, J., Kähäri, V.M., Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13 (1999), 781–782.
33. [33] Ushio-Fukai, M., VEGF signaling through NADPH oxidase-derived ROS. Antioxid. Redox Signal 9 (2007), 731–739.
34. [34] Pizzimenti, S., Toaldo, C., Pettazzoni, P., Dianzani, M., Barrera, G., The “two-faced” effects of reactive oxygen species and the lipid peroxidation product 4-hydroxynonenal in the hallmarks of cancer. Cancer 2 (2010), 338–363.
35. [35] Jaganjac, M., Poljak-Blazi, M., Zarkovic, K., Schaur, R.J., Zarkovic, N., The involvement of granulocytes in spontaneous regression of Walker 256 carcinoma. Cancer Lett. 260 (2008), 180–186.
36. [36] Jaganjac, M., Poljak-Blazi, M., Zarkovic, K., Schaur, R.J., Borovic, S., Matijevic, T., et al. Elevated neutrophil elastase and acrolein-protein adducts are associated with W256 regression. Clin. Exp. Immunol. 170 (2012), 178–185.
37. [37] Zarkovic, K., Uchida, K., Kolenc, D., Hlupic, Lj, Zarkovic, N., Tissue distribution of lipid peroxidation product acrolein in human colon carcinogenesis. Free Radic. Res. 40 (2006), 543–552.
38. [38] Zarkovic, N., Ilic, Z., Jurin, M., Schaur, R.J., Puhl, H., Esterbauer, H., Stimulation of HeLa cell growth by physiological con¬centrations of 4-hydroxynonenal. Cell Biochem. Funct. 11 (1993), 279–286.
39. [39] Borovic, S., Rabuzin, F., Waeg, G., Zarkovic, N., Enzyme-linked immunosorbent assay for 4-hydroxynonenal-histidine conjugates. Free Radic. Res. 40 (2006), 809–820.
40. [40] Sovic, A., Borovic, S., Loncaric, I., Kreuzer, T., Zarkovic, K., et al. The carcinostatic and proapoptotic potential of 4-hydroxynonenal in HeLa cells is associated with its conjugation to cellular proteins. Anticancer Res. 21 (2001), 1997–2004.
41. [41] Jaganjac, M., Čačev, T., Čipak, A., Kapitanović, S., Gall Trošelj, K., Žarković, N., Even stressed cells are individuals: second messengers of free radicals in pathophysiology of cancer. Croat. Med. J. 53 (2012), 304–309.
42. [42] Milkovic, L., Cipak Gasparovic, A., Zarkovic, N., Overview on major lipid peroxidation bioactive factor 4-hydroxynonenal as pluripotent growth regulating factor. Free Radic. Res. 49 (2015), 850–860.
43. [43] Gęgotek, A., Nikliński, J., Žarković, N., Žarković, K., Waeg, G., et al. Lipid mediators involved in the oxidative stress and antioxidant defence of human lung cancer cells. Redox Biol. 9 (2016), 210–219.
44. [44] Zhong, H., Xiao, M., Zarkovic, K., Zhu, M., Sa, R., Lu, J., Tao, Y., Chen, Q., Xia, L., Cheng, S., Waeg, G., Zarkovic, N., Yin, H., Mitochondrial control of apoptosis through modulation of cardiolipin oxidation in hepatocellular carcinoma: a novel link between oxidative stress and cancer. Free Radic. Biol. Med. 176 (2017), 67–76.